LOTTE BIOLOGICS located in East Syracuse, NY is seeking Scientist, Materials Science to join our team who entered the biologics Contract Development Manufacturing Organization (CDMO) business after acquiring Bristol Myers Squibb’s Syracuse biologics drug substance manufacturing site, on January 1, 2023!
The Scientist, Materials Science within Manufacturing Sciences and Technology (MSAT) is responsible for leading MSAT material science and readiness activities for technical transfer, process development, process validation, and GMP manufacturing. The candidate will be the subject matter expert for raw materials (RMs), single-use technologies (SUTs), excipients, and consumables for process development, as well as late-stage and commercial drug substance manufacturing of biopharmaceuticals. The Scientist will work in collaboration with process development and MSAT, site operations, supply chain, procurement, QC/QA, and customers to design, evaluate, and validate these materials. Additionally, the Scientist will drive SUT and RM process standardization, strategy sourcing, and control strategy in collaboration with cross-functional teams using in-depth knowledge of industry best practices and regulatory guidelines. The Scientist will also be accountable for material readiness activities, including but not limited to, review and/or authorship of material and consumable-related risk assessments, material suitability assessments, material shelf program, material storage conditions, material particle profile, elemental impurity assessments, review supplier change notifications for impact, and review new/modified consumables design drawings. The Scientist will also lead and author study protocols and final reports for extractables and leachables, and container closure assessments to support the product lifecycle.
Education/Experience:
Physical Demands:
Work Environment:
Travel:
This position requires up to 10% of domestic and/or international travel.
Work Location:
East Syracuse, NY
LOTTE BIOLOGICS was established in 2022, and is headquartered in Seoul, South Korea. LOTTE BIOLOGICS entered the biologics CDMO business after acquiring Bristol Myers Squibb’s Syracuse biologics drug substance manufacturing site, as of January 1, 2023!
The newly established organization aims to become a Global Top 10 CDMO company in the biopharmaceutical industry. With initial operations in 1948 in Japan, LOTTE has grown to become the fifth-largest conglomerate corporation in South Korea. LOTTE has various business units, including petro/fine chemicals, food, retail, hotels, electronics, construction, and IT. LOTTE has 30+ global locations across the US, Europe, and Asia.
An Equal Opportunity Employer
We do not discriminate based on race, color, religion, national origin, sex, age, disability, genetic information, or any other status protected by law or regulation. It is our intention that all qualified applicants are given equal opportunity and that selection decisions be based on job-related factors.
Software Powered by iCIMS
www.icims.com